Trial Profile
Safety and efficacy of S-1 and gemcitabine in an unselected Caucasian cohort of patients with unresectable pancreatic adenocarcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2019
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Gemcitabine
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 05 Oct 2015 New trial record